BT-690 (subset of GSE272261 - GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant [RNA-Seq], see all subsets)
Annotations: | dimethyl sulfoxide, brain, glioma, bulk RNA-seq assay, gene knockdown CDK6 [human] cyclin-dependent kinase 6, Ribociclib | ||||||
Description: |
Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34), are uniformly lethal malignancies lacking targeted therapies. These gliomas uniquely originate from interneuronal precursor cells, and leveraging this interneuronal lineage origin for mechanistic and therapeutic insights is a pressing need. Here, we elucidate the cell state composition of DHG-H3G34, resolving a cellular hierarchy along continuous interneuron lineage development. In the developing human brain, interneuron lineage precursors form characteristic histological patterns organized in streams of progenitor cells surrounding nests of migratory interneurons, and we find these same spatial patterns to be mirrored in primary DHG-H3G34 tumors. We integrated these findings with genome-wide CRISPR-Cas9 screens, which revealed the majority of dependencies to be genes upregulated in interneuron lineage progenitors, highlighting these as a driver of DHG-H3G34. We validated the essentiality of these lineage-associated targets in patient-derived in vitro and in vivo models. Among these, CDK6 emerged as a targetable dependency, and we demonstrated enhanced sensitivity of DHG-H3G34 tumor cells to CDK4/6 inhibitors and a CDK6-specific degrader. Inhibition of CDK6 shifted cells towards more mature interneuron-like cell states, reduced tumor growth, and prolonged survival of patient-derived xenografts. Concordantly, a patient with progressive DHG-H3G34 under second line therapy was treated with a CDK4/6 inhibitor, and exhibited stable disease for 17 months. Collectively, we identify interneuronal progenitor-like states, organized in characteristic developmental spatial niches, as a distinct vulnerability consistently upregulated in DHG-H3G34 tumors, and provide initial evidence for CDK6 as a clinically actionable target particularly relevant for its interneuronal developmental biology.
At time of import, last updated (by provider) on: Aug 01 2024
Contributors: ; [Rebecca F Rogers, Gustavo Alencastro Veiga Cruzeiro, Lynn Bjerke, Alan Mackay, Mariella G Filbin, Ilon Liu, Yura Grabovska, Chris Jones] (inherited)
|
||||||
Accession: |
GSE272261 ![]() |
||||||
Publication: | No publication/i> | ||||||
Dimension: | 45029 (27/57 samples) | ||||||
Other subsets: | Assays: |
LOC105369736 KDELR1 SLC30A7 LOC105374894 SDC3 MAP1LC3C OCRL KIT LOC105370234 KIAA1143 LINC00485 LCE3D HLA-H SLC39A9 BACH1 PPIAP60 LOC124905374 MAB21L3 KIF1B LOC105377622 BT690_shRNA2_CDK6_rep3 BT690_shRNA1_CDK6_rep3 BT690_CDK6deg_rep2 BT690_DMSO_CDK6deg_rep2 BT690_DMSO_ABE_rep2 BT690_CDK6deg_rep3 BT690_DMSO_CDK6deg_rep3 BT690_shRNA2_CDK6_rep1 BT690_shRNA1_CDK6_rep1 BT690_shRNA_scramble_rep2 BT690_RIBO_rep1 BT690_DMSO_RIBO_rep2 BT690_ABE_rep2 BT690_CDK6deg_rep1 BT690_DMSO_ABE_rep3 BT690_shRNA1_CDK6_rep2 BT690_DMSO_RIBO_rep3 BT690_RIBO_rep3 BT690_DMSO_ABE_rep1 BT690_RIBO_rep2 BT690_ABE_rep1 BT690_DMSO_RIBO_rep1 BT690_DMSO_CDK6deg_rep1 BT690_shRNA2_CDK6_rep2 BT690_shRNA_scramble_rep3 BT690_ABE_rep3 BT690_shRNA_scramble_rep1 |
|||||
Annotations: |
|